News All News

Attivare, a startup advancing a portfolio of technologies developed at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Massachusetts General Hospital, has shown promising results in cancer clinical trials and is developing a malaria vaccine. Through decades of innovation and cross-disciplinary collaboration, the technology has the potential to fight cancer more effectively or prevent pathogen-related infections. 

Harvard University has expanded a research alliance agreement with Northpond Labs to fund translational research, accelerate commercialization, and advance breakthrough healthcare innovations across Harvard labs at the Wyss Institute, Harvard Medical School, John A. Paulson School of Engineering and Applied Sciences, and Faculty of Arts and Sciences.

A research team led by Christina Woo, professor of chemistry and chemical biology, in collaboration with a team of scientists at pharmaceutical company GSK and Scripps Research Institute, discovered a hidden binding pocket on the protein cereblon. The discovery of the allosteric cereblon binder could uncover a new area of cereblon biology to explore for cancer drugs.

BioMed X and Harvard launched a pilot initiative under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements.